n-Lorem Foundation Welcomes Amy McCooe to its Board of Directors
April 26, 2022
Amy McCooe’s leadership in integrating patient communities and research organizations will enhance n-Lorem’s mission to create a community of care for nano-rare patients
SAN DIEGO, Calif., Apr. 21, 2022, (Business Wire) — n-Lorem, a nonprofit foundation, discovering and providing experimental antisense oligonucleotides (ASOs) to nano-rare disease patients (1 to 30 patients worldwide) for free for life, today announced that Amy McCooe has joined its Board of Directors.
“Through our work at the Wolverine Foundation, we have facilitated the advancement of biological understanding of neurodevelopmental diseases and are dedicated to supporting n-Lorem’s research and ASO discovery efforts,” said Amy McCooe, executive director of The Wolverine Foundation. “I am honored to join the Board of Directors at n-Lorem. This is an amazing group of industry and academic leaders committed to n-Lorem’s novel non-profit approach designed to ease the financial burden of lifelong treatment on the patient and the healthcare system.”
“I am pleased to welcome Amy to our team of dedicated directors. Amy’s expertise in directing a non-profit foundation and working closely with patient communities makes her an excellent fit for our Board of Directors, which is comprised of esteemed leaders in the scientific, investment, regulatory and biotechnology communities,” said Stanley T. Crooke, M.D., Ph.D., Founder, CEO and Chairman, n-Lorem Foundation. “I am grateful to our Board for their guidance as we pioneer a new non-profit model designed to address the needs of nano-rare patients, who would otherwise have limited, if any, options. Not only is n-Lorem working hard to discover and develop personalized ASO medicines for our nano-rare patients, but we are also creating a community of care and support.”
Learn more about n-Lorem’s mission at www.nlorem.org, and please consider giving to n-Lorem to bring hope, possibility and treatment options to these needy patients and families.
- Watch: n-Lorem Foundation: Offering Hope and Help to Nano-rare Patients
- Watch: n-Lorem Foundation Delivers Hope and Treatment for Patient with Nano-Rare Disease
About Amy McCooe
Ms. McCooe joins n-Lorem with over 10 years of experience in building high-performance teams with the ability to motivate, influence and lead multiple groups to achieve exceptional results. As executive director of The Wolverine Foundation, Ms. McCooe provides operational leadership for key partners in the academic research and patient communities that are seeking and/or developing treatments for the MAPK8IP3-Related Neurodevelopmental Disorder. Previously, Ms. McCooe successfully grew an online STEM ED tech company from theory to curriculum implementation in over 1,500 schools, reaching 60,000+ students and successfully landed as a business unit within a major player in the education market. Ms. McCooe holds an M.B.A. from the University of Texas at Austin and a B.A. in history from Trinity College-Hartford.
n-Lorem Foundation is a non-profit organization established to apply the efficiency, versatility and specificity of antisense technology to charitably provide experimental antisense oligonucleotide (ASO) medicines to treat nano-rare patients diagnosed with diseases that are the result of a single genetic defect unique to only one or very few individuals. Nano-rare patients describe a very small group of patients (1-30 worldwide) who, because of their small numbers, have few if any treatment options. n-Lorem Foundation was created to provide hope to these nano-rare patients by developing individualized ASO medicines, which are short strands of modified DNA that can specifically target the transcripts of a defective gene to correct the abnormality. The advantage of experimental ASO medicines is that they can be developed rapidly, inexpensively and are highly specific. To date, n-Lorem has assisted in the development and treatment of 14 nano-rare patients and received over 100 applications for treatment with more than 40 nano-rare patients approved. n-Lorem was founded by Stanley T. Crooke, M.D., Ph.D., former chairman and CEO of Ionis Pharmaceuticals, who founded Ionis Pharmaceuticals in 1989 and, through his vision and leadership, established the company as the leader in RNA-targeted therapeutics. Follow us on Twitter, Facebook, LinkedIn and YouTube.
Amy Williford, Ph.D.
Director of Communications
Executive Director, The Wolverine Foundation
We cannot do
Together we are changing the world—
one patient at a time
We hope that you join us on this journey to discover, develop and provide individualized antisense medicines for free for life for nano-rare patients. The ultimate personalized medicine approach – for free, for life.
Follow us on social for updates on our latest efforts